Foundation Medicine Announces Presentations at ASCO
--Data Supports Comprehensive Genomic Profiling for Identifying Therapeutic Treatment Options and Determining Predictors of Therapeutic Response Across Broad Cancer Types--
The schedule for oral presentations by
Date and Time:
Title: PD-L1 Expression, Cancer Genome Atlas (TCGA) Subtype and Mutational Load are Independent Predictors of Response to Atezolizumab (atezo) in Metastatic Urothelial Carcinoma (mUC; IMvigor210)
Abstract Number: 104
Location: Hall D1
Session: Immunotherapy: Now We're Getting Personal - Using Genomics and Biomarkers to Predict Response
Session Type: Clinical Science Symposium
Presenter:
Collaborator(s):
Date and Time:
Title: Hybrid Capture-Based Next-Generation Sequencing (HC NGS) in Melanoma to Identify Markers of Response to Anti-PD-1/PD-L1
Abstract Number: 105
Location: Hall D1
Session: Immunotherapy: Now We're Getting Personal - Using Genomics and Biomarkers to Predict Response
Session Type: Clinical Science Symposium
Presenter:
Collaborator(s):
The schedule for poster discussions by
Date and Time:
Discussion Time: 3:00 -
Title: Genomic Profiling to Distinguish Poorly Differentiated Neuroendocrine Carcinomas Arising in Different Sites
Abstract Number: 4020
Poster Board Number: 12
Poster Display Location: Hall A
Discussion Location: Hall D1
Session: Gastrointestinal (Noncolorectal) Cancer
Presenter: Emily K. Bergsland, M.D., endowed chair in medical oncology,
Collaborator(s):
Date and Time:
Discussion Time: 3:00 -
Title: Total Mutation Burden (TMB) in
Abstract Number: 9017
Poster Board Number: 340
Poster Display Location: Hall A
Discussion Location: E354b
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter:
Collaborator(s):
Date and Time:
Discussion Time: 3:00 -
Title: Comprehensive Genomic Profiling of 298 Lung Cancers of Varying Histologies Harboring MET Exon 14 Alterations
Abstract Number: 9021
Poster Board Number: 344
Poster Display Location: Hall A
Discussion Location: E354b
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter:
Collaborator(s):
Date and Time:
Discussion Time: 4:45 -
Title: Comprehensive Genomic Sequencing (CGS) of 90 Patient Samples of Anaplastic Thyroid Cancer (ATC)
Abstract Number: 6014
Poster Board Number: 336
Poster Display Location: Hall A
Discussion Location: S406
Session: Head and Neck Cancer
Presenter: Saad A. Khan, M.D., medical oncologist,
Collaborator(s):
Date and Time:
Discussion Time: 1:15 -
Title: Evaluation of Microsatellite Instability (MSI) Status in 11,573 Diverse Solid Tumors using Comprehensive Genomic Profiling (CGP)
Abstract Number: 1523
Poster Board Number: 346
Poster Display Location: Hall A
Discussion Location: S404
Session: Cancer Prevention, Hereditary Genetics and Epidemiology
Presenter:
Collaborator(s):
Date and Time:
Discussion Time: 4:45 -
Title: DNA-Based Genomic Profiling for Classification of Tissue of Origin for Patients with Carcinoma of Unknown Primary Site
Abstract Number: 11519
Poster Board Number: 216
Poster Display Location: Hall A
Discussion Location: S406
Session: Tumor Biology
Presenter: Michael Goldberg, clinical data analyst II cancer genomics,
The schedule for poster presentations by
Date and Time:
Title: Tumor Mutational Burden as a Potential Biomarker for PD-11/PD-L1 Therapy in Colorectal Cancer
Abstract Number: 3587
Poster Board Number: 284
Poster Display Location: Hall A
Session: Gastrointestinal (Colorectal) Cancers
Presenter: Thomas J. George, M.D., F.A.C.P., medical director, gastrointestinal oncology,
Collaborator(s):
Date and Time:
Title: Genomic Distinctions Between Colon and Rectal Cancer in Young Patients
Abstract Number: 3574
Poster Board Number: 271
Poster Display Location: Hall A
Session: Gastrointestinal (Colorectal) Cancer
Presenter: Joshua E. Meyer, M.D., assistant professor; residency/fellowship training director, department of radiation oncology,
Collaborator(s):
Date and Time:
Title: MDM2 Amplification (Amp) to Mediate Cabozantinib Resistance in Patients (Pts) with Advanced RET-Rearranged Lung Cancers
Abstract Number: 9068
Poster Board Number: 391
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small cell Metastatic
Presenter:
Collaborator(s):
Date and Time:
Title: Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, Demographics, and Molecular Markers
Abstract Number: 9088
Poster Board Number: 411
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter: Vassiliki Papadimitrakopoulou, M.D., professor, department of thoracic/head and neck medical oncology, medical oncology,
Collaborator(s):
Date and Time:
Title: Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC).
Abstract Number: 3589
Poster Board Number: 286
Poster Display Location: Hall A
Session: Gastrointestinal (Colorectal) Cancer
Presenter: Christopher Hanyoung Lieu, M.D., director, Colorectal Medical Oncology Program, deputy director, Cancer Clinical Trials Office,
Collaborator(s):
Date and Time:
Title: Significant Systematic and CNS Activity of the RET Inhibitor Vandetanib Combined with mTOR inhibitor Everolimus in Patients with Advanced NSCLC with RET fusion
Abstract Number: 9069
Poster Board Number: 392
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter:
Collaborator(s):
Date and Time:
Title: TMPRSS-ERG Fusion in Men with Prostate cancer(PCa) and Non-prostate Malignancies: Defining a role for Comprehensive Genomic Profiling (CGP) to guide Clinical Care
Abstract Number: 5037
Poster Board Number: 294
Poster Display Location: Hall A
Session: Genitourinary (Prostate) Cancer
Presenter: Primo
Collaborator(s):
Date and Time:
Title: Analysis of Tumor Mutational Burden (TMB) in > 51,000 Clinical Cancer Patients to identify Novel Non-Coding PMS2 Promoter Mutations Associated with increased TMB
Abstract Number: 9572
Poster Board Number: 177
Poster Display Location: Hall A
Session: Melanoma/Skin Cancers
Presenter: Zachary Rockow Chalmers, senior research associate,
Date and Time:
Title: Comprehensive Genomic Profiling of Neuroendocrine Carcinoma of the Prostate
Abstract Number: 5027
Poster Board Number: 284
Poster Display Location: Hall A
Session: Genitourinary (Prostate) cancer
Presenter: Philip J. Stephens, Ph.D., chief scientific officer,
Date and Time:
Title: Deep Sequencing of Metastatic Cutaneous Basal Cell and Squamous Cell Carcinomas to Reveal Distinctive Genomic Profiles and New Routes to Targeted Therapies
Abstract Number: 9522
Poster Board Number: 127
Poster Display Location: Hall A
Session: Melanoma/Skin Cancers
Presenter: Jeffrey S. Ross, M.D., medical director,
Collaborator(s):
Date and Time:
Title: The Genomics of Young
Abstract Number: 9083
Poster Board Number: 406
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter:
Collaborator(s):
Date and Time:
Title: Biomarkers of Immune Checkpoint Inhibitor Response in Metastatic Breast Cancer: PD-L1 Protein Expression, CD274 Gene Amplification, and Total Mutational Burden
Abstract Number: 3057
Poster Board Number: 379
Poster Display Location: Hall A
Session:
Presenter:
Collaborator(s):
Date and Time:
Title: Distinct Age-Associated Genomic Profiles Identified in Acute Myeloid Leukemia (AML) Using FoundationOne Heme
Abstract Number: 7041
Poster Board Number: 33
Poster Display Location: Hall A
Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant
Presenter: Katherine Tarlock, M.D., acting instructor, hematology-oncology, Seattle Children's Hospital
Collaborator(s):
Date and Time:
Title: Comparison of Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder to Reveal Key Differences in Mutational Profile and Load
Abstract Number: 4522
Poster Board Number: 145
Poster Display Location: Hall A
Session: Genitourinary (Nonprostate) Cancer
Presenter: Sumanta K. Pal, M.D., assistant clinical professor, department of medical oncology & therapeutics research,
Collaborator(s):
Date and Time: Monday,
Title: Assessment of Tumor Mutation Burden from > 60,000 Clinical Cancer Patients Using Comprehensive Genomic Profiling
Abstract Number: 11558
Poster Board Number: 255
Poster Display Location: Hall A
Session: Tumor Biology
Presenter: Garrett Michael Frampton, Ph.D., associate director, bioinformatics,
Date and Time:
Title: Immunotherapy (IO) Versus Targeted Therapy Triage in Advanced Endometrial Adenocarcinoma (aEA) by Coordinate Assessment Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) Status, and Targetable Genomic Alterations (GA)
Abstract Number: 5591
Poster Board Number: 414
Poster Display Location: Hall A
Session: Gynecologic Cancer
Presenter: Alessandro Santin, M.D., professor of obstetrics, gynecology and reproductive sciences; clinical research program leader, gynecologic oncology program,
Collaborator(s):
Date and Time:
Title: Comprehensive Genomic Profiling to Identify Clinically Relevant Genomic Alterations in Patients with Advanced Penile Cancers
Abstract Number: 4573
Poster Board Number: 195
Poster Display Location: Hall A
Session: Genitourinary (Nonprostate) Cancer
Presenter: Andre Poisl Fay, M.D.
Collaborator(s): Pontifícia Universidade Católica do Rio Grande do
Date and Time:
Title: Decision Impact Analysis of Comprehensive Genomic Profiling (CGP) in Advanced Breast Cancer: A Prospective Study
Abstract Number: 11578
Poster Board Number: 275
Poster Display Location: Hall A
Session: Tumor Biology
Presenter: Raquel E. Reinbolt, M.D., assistant professor, internal medicine, college of medicine,
Collaborator(s): The
Date and Time:
Title: Investigating the Utility of Comprehensive Genomic Profiling for Patients with Newly Diagnosed Breast Cancer
Abstract Number: TPS11617
Poster Board Number: 312b
Poster Display Location: Hall A
Session: Tumor Biology
Presenter:
Collaborator(s):
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of comprehensive genomic profiling, including FoundationOne, FoundationOne Heme and FoundationACT to identify genomic alterations, identify relevant therapies and improve patient outcomes; and the clinical relevance of comprehensive genomic profiling in cancer treatment and the development of targeted therapies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that the results presented are found to lack scientific, medical or clinical utility or that subsequent research renders the results presented less useful or not useful in clinical practice;
View source version on businesswire.com: http://www.businesswire.com/news/home/20160518006547/en/
Media Contact:
dan@purecommunicationsinc.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media